Aller au contenu principal
Profil bibliographique

Tatsuya Ioka

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

314Publications signalées
6628Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Pancreatic and Hepatic Oncology ResearchCholangiocarcinoma and Gallbladder Cancer StudiesGallbladder and Bile Duct DisordersPancreatitis Pathology and TreatmentCancer Genomics and Diagnostics

Les publications récentes

2026 article OpenAlex

[Perioperative Immunotherapy as a Strategy to Overcome Hepatocellular Carcinoma].

Masao Nakajima, Yukio Tokumitsu, Yoshitaro Shindo, Hiroto Matsui et autres

Hepatocellular carcinoma (HCC) has a high recurrence rate even after curative resection or local ablation, and early recurrence within 1-2 years is often driven by intrahepatic metastasis and strongly affects prognosis. Immune checkpoint inhibitor (ICI)-based combination therapy has become a standard approach …

jp (code pays fourni par la source)

0 citations PubMed
Accès ouvert 2026 article OpenAlex

Reduced-dose nanoparticle albumin-bound-paclitaxel combined with ramucirumab as second-line treatment for advanced gastric cancer: a multicenter phase II study

Michihisa Iida, Chiyo Nakashima, Toru Kawaoka, Junya Kondo et autres

Abstract Background Weekly paclitaxel combined with ramucirumab is the standard second-line chemotherapy regimen for advanced gastric cancer. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is increasingly used as it lowers the risk of hypersensitivity reactions; however, full-dose nab-paclitaxel (100 mg/m²) combined with ramucirumab frequently leads …

jp (code pays fourni par la source)

0 citations BMC Cancer
2026 article OpenAlex

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial

Tanios S. Bekaii-Saab, Davide Melisi, Hanneke Wilmink, Carlo Garufi et autres

PURPOSE Cholangiocarcinoma is a rare cancer associated with poor prognosis. Pemigatinib was the first FGFR1-3 inhibitor approved for second-line therapy and beyond, on the basis of the phase II FIGHT-202 trial. Here, we assess efficacy and safety of first-line pemigatinib. METHODS FIGHT-302 …

us, it, nl, se, es, gb, ca, jp, de (code pays fourni par la source)

3 citations Journal of Clinical Oncology
2026 article OpenAlex

A randomized phase III study of gemcitabine plus cisplatin with S-1 versus gemcitabine plus cisplatin with immune checkpoint inhibitor in unresectable biliary tract cancer.

松井 洋人, Takeshi Terashima, Takashi Mizuno, Yoshiharu Masaki et autres

TPS4252 Background: Gemcitabine plus cisplatin (GC) has been established as the standard first-line treatment for unresectable biliary tract cancer (BTC). Recent phase III trials have demonstrated the clinical benefit of adding immune checkpoint inhibitors (ICIs) to GC. Meanwhile, GC combined with S-1 …

jp (code pays fourni par la source)

0 citations Journal of Clinical Oncology
2026 article OpenAlex

Immature Peritumoral Tertiary Lymphoid Structures Indicate Poor Prognosis in Pancreatic Ductal Adenocarcinoma After NAC

Mari Nabeya, MASAO NAKAJIMA, Ryouichi Tsunedomi, Takahiro Ozasa et autres

Background/Aim: Tertiary lymphoid structures (TLSs) have prognostic relevance in various cancers; however, the relationship is complex and depends on TLS properties. In this study, we evaluated the prognostic significance of TLS spatial distribution and maturation in patients with pancreatic ductal adenocarcinoma (PDAC) …

jp (code pays fourni par la source)

1 citation Anticancer Research
Accès ouvert 2026 article OpenAlex

Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II trials (JCOG2408A)

Yusuke Sano, Riku Kajikawa, Junki Mizusawa, Tatsuya Ioka et autres

BACKGROUND: Two main therapeutic approaches are currently used for locally advanced pancreatic cancer (LAPC): chemoradiotherapy and systemic chemotherapy. It remains unclear which approach may be more promising, or whether these strategies should be considered alternative or complementary therapeutic options in the management …

jp (code pays fourni par la source)

1 citation BMC Cancer
Accès ouvert 2026 other OpenAlex

Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II trials (JCOG2408A)

Yusuke Sano, Riku Kajikawa, Junki Mizusawa, Tatsuya Ioka et autres

Abstract Background Two main therapeutic approaches are currently used for locally advanced pancreatic cancer (LAPC): chemoradiotherapy and systemic chemotherapy. It remains unclear which approach may be more promising, or whether these strategies should be considered alternative or complementary therapeutic options in the …

jp (code pays fourni par la source)

0 citations Figshare
Accès ouvert 2026 other OpenAlex

Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II trials (JCOG2408A)

Yusuke Sano, Riku Kajikawa, Junki Mizusawa, Tatsuya Ioka et autres

Abstract Background Two main therapeutic approaches are currently used for locally advanced pancreatic cancer (LAPC): chemoradiotherapy and systemic chemotherapy. It remains unclear which approach may be more promising, or whether these strategies should be considered alternative or complementary therapeutic options in the …

jp (code pays fourni par la source)

0 citations Figshare
2026 article OpenAlex

[A Case of Hyperammonemia Induced by 5‒FU in a Patient with Advanced Rectal Cancer].

Akira Ishii, Shinobu Tomochika, Yasuhiro Fujiwara, Hironori Tanaka et autres

A 74‒year‒old male was diagnosed with advanced rectal cancer with bowel obstruction, and abscess formation. After sigmoid colostomy, FOLFOXIRI plus bevacizumab as preoperative chemotherapy was initiated. On day 3, during continuous administration of 5‒fluorouracil(5‒FU), the patient developed impaired consciousness accompanied by convulsive …

jp (code pays fourni par la source)

0 citations PubMed
Accès ouvert 2026 article OpenAlex

Refining Outcomes in Technically Resectable Colorectal Liver Metastases: A Simplified Risk Model and the Role of Preoperative Chemotherapy

Kou Kanesada, Masao Nakajima, Tatsuya Ioka, Shinobu Tomochika et autres

Background: Preoperative chemotherapy is increasingly used for colorectal liver metastases (CRLM), but simple risk stratification tools for routine practice remain limited. We developed a simple risk model to predict outcomes after curative-intent CRLM resection, including in patients receiving preoperative chemotherapy. Methods: We …

jp (code pays fourni par la source)

0 citations Cancers

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.